Home Medicine Morgan Stanley Adjusts Editas Medicine’s Price Target to $7 From $8, Keeps Underweight Rating

Morgan Stanley Adjusts Editas Medicine’s Price Target to $7 From $8, Keeps Underweight Rating

by Universalwellnesssystems


MT Newswire 2023

All news about EDITAS MEDICINE, INC.

ANALYST RECOMMENDATIONS FOR EDITAS MEDICINE, INC.

Sale 2022 16,6M

net income 2022 -215M

NetCash 2022 316M

PER 2022 -2,62x
Yield 2022
capitalization 550M
550M
EV / Sale 2022 14,1x
EV / Sale 2023 20,9 times
number of employees 264
free float 99.5%

Chart EDITAS MEDICINE, INC.


Interval:

Period:




Editas Medicine, Inc. Technical Analysis Chart | Market Screener

Technical Analysis Trends Editas Medicine Co., Ltd.

Short term Middle term long term
trend bearish bearish bearish

Income Statement Evolution

sell

buy

average consensus possession
number of analysts 19
Final closing price 8,18$
average target price 14,13$
Spread/Average Target 72.7%


You may also like

Leave a Comment

The US Global Health Company is a United States based holistic wellness & lifestyle company, specializing in Financial, Emotional, & Physical Health.  

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Copyright ©️ All rights reserved. | US Global Health